# KLOW Meds — Independent research summary of the GHK-Cu + BPC-157 + TB-500 + KPV blend > An editorial reference plate for the KLOW research peptide blend: four components, no combination study, individual-component evidence drawn to scale. Research-only. KLOW is a fixed-ratio research formulation: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg in an 80 mg lyophilized vial. No published in-vivo combination study exists. This site is a four-sheet reference plate of what the monotherapy literature actually shows. ## Blueprint summary KLOW is a four-peptide research blend supplied as one lyophilized vial — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg, eighty milligrams total. Each component is a different molecule with a different mechanism and a different literature base: matrix remodeling (GHK-Cu), angiogenesis and connective-tissue repair (BPC-157), cell migration (TB-500), and inflammation suppression (KPV). None of the four is FDA-approved for any indication. The blend itself has never been tested in a controlled study — all four-arm combination claims are mechanistic extrapolations from single-component data. The four component literatures — rodent models, a handful of small human pilots, and one topical cosmetic record — are the only evidence that exists. What people who use KLOW as a research material report, and who has a documented reason for caution, is on [the effects page](/effects). ## Part 01 — What KLOW is KLOW is a four-peptide research blend supplied as a single lyophilized vial. The dominant commercial composition across the major research-chemical suppliers is GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg — eighty milligrams total, mass-ratio 50:10:10:10 [6,9,1,14]. The acronym is vendor-coined. An alternate 'KPV + Larazotide + GHK-Cu + BPC-157' composition appears in early hobbyist documentation but is not the formulation reflected in current supplier listings, and larazotide acetate is a separate tight-junction-modulating peptide that failed its Phase 3 celiac trial in 2022. The four components do not share a target, a pathway, or a tissue. GHK-Cu is a copper-binding tripeptide first isolated from human plasma in 1973 [6]. BPC-157 is a 15-amino-acid sequence derived from a fragment of human gastric juice protein [4]. TB-500 is the commercial label for synthetic thymosin beta-4, a 44-amino-acid actin-sequestering peptide [10,11]. KPV is the three-residue C-terminal fragment of alpha-melanocyte-stimulating hormone — Lys-Pro-Val — that retains the parent hormone's anti-inflammatory activity without binding melanocortin receptors [14,16]. What KLOW is *not*: an FDA-approved drug, a compounded prescription medication, or a substance with any in-vivo combination study supporting its 50:10:10:10 ratio. KLOW Meds is an editorial reference. We do not manufacture, sell, or distribute peptides. ## Part 02 — Why a four-peptide blend at all The mechanistic rationale offered by vendors and hobbyist documentation is that the four components target non-overlapping aspects of tissue repair and inflammation. GHK-Cu drives matrix remodeling, fibroblast activation, and angiogenesis [6,7,9]. BPC-157 activates the VEGFR2-Akt-eNOS angiogenic axis in cell culture and improves tendon-to-bone healing in rats [1,2,4]. TB-500 sequesters G-actin via its LKKTET motif, enabling cell migration and reducing scar formation in dermal wound models [10,11]. KPV suppresses NF-kB to dampen TNF-alpha, IL-1-beta, and IL-6 output in inflamed tissue [14,15,16]. That is the rationale. The evidence for the rationale is monotherapy-only. No peer-reviewed in-vivo study of the four-peptide combination has been published. Any claim about KLOW *synergy* is mechanistic speculation, not direct evidence. ## Part 03 — What the research record actually contains Component-by-component, the literature is uneven. BPC-157 has the largest preclinical base — a 2025 HSS Journal systematic review screened 544 articles and included 36, of which 35 were preclinical and one was a retrospective clinical case series of 12 patients [19]. The authors concluded BPC-157 should not yet be recommended for clinical musculoskeletal use pending controlled human trials. TB-500 has the most human data of the four. A randomized, placebo-controlled Phase 1 study of intravenous thymosin beta-4 in healthy volunteers found no serious adverse events across single doses from 42 mg to 1260 mg and a multiple-dose 14-day regimen [12]. An ophthalmic Phase 3 trial of 0.1% RGN-259 (thymosin beta-4 eye drops) in neurotrophic keratopathy met its primary endpoint in a US study [13]; a separate European Phase 3 SEER-3 trial in neurotrophic keratitis missed its primary endpoint, attributed to an unusually strong placebo response. A 2025 cardiac trial reported measurable improvement in left-ventricular function in STEMI patients who received IV thymosin beta-4 within 12 hours of PCI [18]. GHK-Cu has small dermatologic and cosmetic studies and a deep mechanistic literature on gene-expression modulation — a Connectivity Map analysis showed GHK reverted a 127-gene COPD-severity signature toward the healthy baseline [8]. KPV has no published human clinical trial data; its evidence base is rodent colitis models, where oral KPV in drinking water reduced colon inflammation markers by approximately 50% [14] and reduced tumor count in a colitis-associated cancer model [15]. KPV is scheduled for FDA Pharmacy Compounding Advisory Committee review in mid-2026. What the record does not contain: a single peer-reviewed study of GHK-Cu + BPC-157 + TB-500 + KPV co-administered at any ratio. ## Part 04 — Regulatory status, at a glance None of the four components holds FDA approval for any indication. BPC-157 was placed in FDA Category 2 of the 503A Interim Bulks Guidance in September 2023, halting compounding-pharmacy production; it was removed from Category 2 in April 2026 after nominators withdrew their nominations, but it remains an unapproved drug substance. BPC-157 and TB-500 are both prohibited under WADA category S0 (Non-Approved Substances), banned at all times in and out of competition for athletes. KPV and GHK-Cu are not explicitly listed by WADA, but any non-approved pharmacological substance is captured by S0 in principle. There is no European Medicines Agency approval for any of the four components or for any KLOW-style blend. The blend itself has no regulatory standing of any kind. KLOW is a research-only formulation. ## Part 05 — How to read this set Six sheets follow the title page. /components lays out each peptide as its own annotated sub-assembly. /research walks the underlying study record component by component. /dosage documents the research-context doses and routes that have been used in the published literature, with no instruction for human use. /faq answers the ten questions readers ask most. /references holds the full citation list with DOIs. /about explains who publishes this site and why. KLOW Meds is not a clinic, not a pharmacy, and not a vendor. The 'meds' modifier is editorial framing — the position the publisher occupies relative to the literature, not a claim about the site's services. --- A technical reference set for the peer-reviewed literature — not a clinic, not a vendor, not a prescription.